Most With AD, MCI Would Have Been Excluded From Aducanumab Clinical Trials
Overall, 92.2, 91.0, and 85.5 percent of Medicare beneficiaries with ADRDs, Alzheimer disease, and MCI met at least one of the exclusion criteria
Alzheimer Disease and Dementia
DPP-4i Use May Protect in Alzheimer Dementia With Diabetes
Low amyloid burden and favorable cognitive outcomes seen with DPP-4i use in Alzheimer disease-related cognitive impairment with diabetes
Two Major Health Systems Will Not Administer Controversial Aduhelm
Individual doctors can prescribe Aduhelm, but patients would have to go elsewhere to receive the drug via infusion
AAN Presents Ethical Considerations Relating to Dementia Care
Timely anticipatory planning in early dementia is crucial to preserve autonomy over future decisions and to reduce caregiver strain
MPR Weekly Dose Podcast Episode 85
This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there’s updates to the cancer drug Keytruda.
House Committees to Investigate New Alzheimer Disease Drug Approval
FDA approved Aduhelm earlier this month, despite advisory committee’s conclusion that there was not enough evidence to support its effectiveness
Three FDA Advisers Quit Over Agency Approval of Aduhelm
Several experts have said the available evidence about Aduhelm raises significant doubts about its effectiveness
MPR Weekly Dose Podcast 81
This week’s episode covers the aducanumab approval. There’s also approvals in treatments for obesity and a first treatment for Plasminogen Deficiency Type 1. Plus, Moderna have sent an EUA request to extend use of their COVID-19 vaccine to those aged 12 and older.
Gene Therapy Fast Tracked for APOE4 Associated Alzheimer Disease
The investigational adeno-associated virus mediated gene therapy is being developed to deliver the protective APOE2 gene to the CNS.
Donanemab Studied in Early Symptomatic Alzheimer Disease
Slightly less cognitive and functional decline seen with donanemab versus placebo at 76 weeks in phase 2 trial
